INFO & CONTACTS:  +39 02 2390 1

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

Phase: Phase I-II clinical trials

Principal Investigator: Dott.ssa Damian Silvia

Main Facility: Unità Studi Clinici di Fase 1 (Early clinical Drug Development Team-ECDD)

Drug: S241656 (BDTX-4933)

Pathologies: Advanced Solid Tumours

ClinicalTrials.gov: Read the details about clinical trials

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with standard of care in adult participants with selected advanced/metastatic malignancies harboring KRAS, NRAS, HRAS, BRAF, and/or CRAF (RAF1) mutations or alterations.

Last update: 16/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe